The purpose of the study is to evaluate the safety, tolerability and treatment effect of tirbanibulin ointment 1% when applied to a field of approximately 100 cm\^2 on the face or balding scalp.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 5
Timeframe: Baseline, Day 5
Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 8
Timeframe: Baseline, Day 8
Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 15
Timeframe: Baseline, Day 15
Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 29
Timeframe: Baseline, Day 29
Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 57
Timeframe: Baseline, Day 57
Number of Participants With Maximum Local Tolerability Score Post-baseline for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration)
Timeframe: Baseline, Maximum post-baseline (up to Day 57)
Time to Maximum Local Tolerability Score for Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration
Timeframe: Baseline up to Day 57
Local Tolerability Signs Total Composite Score by Visit at Day 5
Timeframe: Baseline, Day 5
Local Tolerability Signs Total Composite Score by Visit at Day 8
Timeframe: Baseline, Day 8
Local Tolerability Signs Total Composite Score by Visit at Day 15
Timeframe: Baseline, Day 15
Local Tolerability Signs Total Composite Score by Visit at Day 29
Timeframe: Baseline, Day 29
Local Tolerability Signs Total Composite Score by Visit at Day 57
Timeframe: Baseline, Day 57
Maximum Local Tolerability Signs Total Composite Score Post Baseline
Timeframe: Baseline, Maximum post-baseline (up to Day 57)
Time to Maximum Local Tolerability Total Composite Score
Timeframe: Baseline up to Day 57
Number of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 5
Timeframe: Baseline, Day 5
Number of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 8
Timeframe: Baseline, Day 8
Number of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 15
Timeframe: Baseline, Day 15
Number of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 29
Timeframe: Baseline, Day 29
Number of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 57
Timeframe: Baseline, Day 57
Number of Participants With Any Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and Adverse Events of Special Interest (AESIs)
Timeframe: Baseline up to Day 57
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters
Timeframe: Baseline up to Day 57
Number of Participants With Clinically Significant Abnormalities in Vital Signs
Timeframe: Baseline up to Day 57
Number of Participants With Clinically Significant Abnormalities in Physical Examination
Timeframe: Baseline up to Day 57
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG)
Timeframe: Baseline up to Day 57